Baldwin Wealth Partners LLC MA Acquires 7,636 Shares of Merck & Co., Inc. (NYSE:MRK)

Baldwin Wealth Partners LLC MA grew its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 4.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 196,756 shares of the company’s stock after acquiring an additional 7,636 shares during the quarter. Merck & Co., Inc. accounts for 1.4% of Baldwin Wealth Partners LLC MA’s portfolio, making the stock its 21st largest holding. Baldwin Wealth Partners LLC MA’s holdings in Merck & Co., Inc. were worth $19,573,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Algert Global LLC acquired a new stake in Merck & Co., Inc. in the 2nd quarter worth $325,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Merck & Co., Inc. by 3.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 312,252 shares of the company’s stock valued at $38,657,000 after buying an additional 9,174 shares during the period. Granite FO LLC acquired a new stake in Merck & Co., Inc. during the second quarter worth about $292,000. Sunbelt Securities Inc. increased its stake in Merck & Co., Inc. by 0.3% during the second quarter. Sunbelt Securities Inc. now owns 53,665 shares of the company’s stock valued at $6,644,000 after acquiring an additional 170 shares during the period. Finally, William B. Walkup & Associates Inc. acquired a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $3,330,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 2.5 %

Shares of NYSE:MRK opened at $97.99 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The firm has a market cap of $247.87 billion, a P/E ratio of 20.54, a P/E/G ratio of 1.13 and a beta of 0.39. Merck & Co., Inc. has a 12 month low of $94.48 and a 12 month high of $134.63. The company’s 50-day moving average price is $99.80 and its two-hundred day moving average price is $108.56.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. The firm had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 36.42% and a net margin of 19.23%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company earned $2.13 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 7.67 EPS for the current fiscal year.

Merck & Co., Inc. Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th were issued a dividend of $0.81 per share. This represents a $3.24 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date was Monday, December 16th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.77. Merck & Co., Inc.’s payout ratio is currently 67.92%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Sanford C. Bernstein started coverage on Merck & Co., Inc. in a research report on Thursday, October 17th. They set a “market perform” rating and a $115.00 price objective on the stock. Morgan Stanley lowered their price target on shares of Merck & Co., Inc. from $123.00 to $113.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 21st. Truist Financial reaffirmed a “hold” rating and set a $110.00 price objective (down from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. Daiwa America cut shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 11th. Finally, Guggenheim cut their price target on shares of Merck & Co., Inc. from $137.00 to $130.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have given a hold rating, nine have assigned a buy rating and four have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

View Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.